Page 13 - Pharma Industry

Natco Pharma Q3 results: Net profit rises over 3-fold to Rs 212.7 crore

Natco Pharma Ltd on Wednesday reported over three-fold rise in consolidated net profit at Rs 212.7 crore in the third quarter ended December 31, 2023 on the back of robust revenue growth. The company had posted a consolidated net profit of Rs 62.3 crore in the same period last fiscal, Natco Pharma said in a regulatory filing. Consolidated revenue from operations in the quarter under review stood at Rs 758.6 crore, as against Rs 492.5 crore in the year-ago period, it added. Total expenses were higher at Rs 539.3 crore, up from Rs 431.9 crore in the same quarter last fiscal, the company said. There was strong growth across businesses compared to last year, Natco said, adding it is confident of its strategy going forward. Revenue from export of formulations was at Rs 605.6 crore in the third quarter, up from Rs 333.7 crore in the year-ago period. However, domestic formulations revenue was down at Rs 99.4 crore, as compared to Rs 101.1 crore in the corresponding period last fiscal, i

Wockhardt Q3 results: Loss narrows to Rs 86 cr, revenue up marginally

Pharmaceuticals firm Wockhardt Ltd on Wednesday reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023. The company had incurred a loss of Rs 102 crore in the third quarter last fiscal, Wockhardt Ltd said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in the year-ago period, the company said. Total expenses were lower at Rs 796 crore as against Rs 803 crore in the same period last fiscal.

Zydus Lifesciences Q3 result: Net profits rise by 27%, beat estimates

Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets

Biocon Biologics partners with Sandoz Australia to sell cancer drugs

The partnership will provide Sandoz the exclusive rights to promote, sell, and distribute biosimilar Trastuzumab and biosimilar Bevacizumab in Australia

Biocon inks pact with Sandoz for sale of 2 biosimilar products in Australia

Biocon Biologics on Friday said it has inked a five-year pact with pharmaceutical company Sandoz AG regarding the sale and distribution of two cancer treatment biosimilar products in Australia. The agreement provides Sandoz the exclusive rights to promote, sell and distribute biosimilars Trastuzumab and Bevacizumab in Australia, Biocon Biologics said in a statement. Biocon Biologics is a subsidiary of Biocon Ltd. Under the agreement, Sandoz will distribute the Biocon Biologics' brands, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), and facilitate the sustained access of these medications that were previously distributed by another pharmaceutical company to patients in Australia. Trastuzumab is a biosimilar of Herceptin and Bevacizumab is a biosimilar of Avastin and utilised for the treatment of various cancers. "Following the recent establishment of our strategic partnership with Sandoz in Japan, our agreement with Sandoz in Australia marks another important milestone of our globa

JB Pharma CEO attributes 3.5% of company's growth to new introductions

"We are growing at 16 per cent, compared to the Indian Pharma Market (IPM) growth of 8 per cent, and a 12 per cent growth of the market which we cover," Chopra said

Lupin Q3 results: Net jumps 300% to Rs 613 cr on back of record sales

Nilesh Gupta, MD, Lupin Limited said, "We delivered our highest quarterly sales to date, crossed the Rs 5,000 crore mark for the first time, driven by strong growth across geographies."

Novo Nordisk buys three plants for $11 billion to boost Wegovy output

Novo's biggest shareholder is buying Catalent Inc., one of the world's biggest drug-manufacturing companies, for $16.5 billion, including debt. In a three-way arrangement

Alembic Pharma Q3 results: Profit up 48% as raw material cost declines

This increase in PAT was attributed to tax deduction, decline in the cost of materials consumed, and improvement in Ebitda

Torrent Pharma Q3 results: Profit after tax up 51% at Rs 443 crore

Torrent Pharmaceuticals' share price rose by 0.51 per cent, ending the day's trade at Rs 2,524 apiece on the Bombay Stock Exchange (BSE)

Sun Pharma Q3 results: Net profit up 16.5% at Rs 2,524 cr on US, India biz

Bloomberg analysts' estimates had pegged the revenue at Rs 12,336 crore and PAT at Rs 2,470 crore

Sun Pharma Q3 results: Net profit increases 15% at Rs 2,524 crore

Sales in its US formulations business rose nearly 15 per cent to Rs 3,974 crore, while sales from its India formulations rose more than 11 per cent to Rs 3,779 crore

Pharmeasy FY23 losses widen 31%, revenue increases 16% to Rs 6,644 cr

Online pharmacy dropped plan for an IPO in 2022, says it is cutting down expenses

Breather for consumers as drug prices likely to remain same this year

In previous two years, hikes were in the range of 10-12%

Indian firms corner more of growing pharma market as MNCs go niche

Indian drug firms are focussing on expanding their salesforce and distri­bution, while getting into trade generics to garner volumes

Govt committed to transform healthcare landscape: Health minister Mandaviya

The government is committed to transform the country's entire healthcare landscape, Health Minister Mansukh Mandaviya said Wednesday, highlighting that this dispensation opened several new AIIMS, raised the number of medical colleges to almost double and operationalised more than 10,000 Jan Aushadhi Kendras. He was speaking after virtually inaugurating a Super Specialty Block at Ganesh Shankar Vidyarthi Memorial Medical College in Kanpur, Uttar Pradesh. He also laid the foundation stone of an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur. "This Super Specialty Block offering 12 super-specialty services will help people take these specialised services locally, saving their valuable time and resources," he said. On the AIISH Centre in Kanpur, he said it will be the first such state-of-the-art centre in North India which will not only train doctors but also provide care to people. It is the dream of Prime Minister Narendra Modi that AIISH institutes be .

Countries risk missing May deadline for pandemic accord, says WHO chief

Only once before in the organisation's 75-year history has the WHO managed to agree such an accord, and that was a Tobacco Control treaty in 2003

India moving towards integrated medicine approach with Ayush: Sonowal

Union Minister Sarbananda Sonowal on Saturday said the country is moving towards an integrated approach where the Ayush system of medicine will be used along with the modern ones. The minister also laid the foundation stone for Ayush Diksha', a first-of-its-kind centre for the development of human resources for ayush professionals in future. The centre will be developed on the campus of Central Ayurveda Research Institute, Bhubaneswar. Sonowal also asserted that the Ayush movement has "gained a lot of prominence" in the last 10 years. We are moving towards an integrated medicine approach where an empowered Ayush system of medicine will also be used along with the modern medicine system," the minister said. The integrated medicinal approach will prove as a "boon for the people of the country" as they can move towards healing their ailments as well as enriching their quality of life by empowering their physical and mental well-being, the minister said. Sonowal, the minister of Ayus

Doctors should be careful of mefenamic acid's effects: Meftal makers

In the backdrop of a caution by the Indian Pharmacopoeia Commission (IPC) against mefenamic acid, a major component of painkiller meftal, the medicine's manufacturer on Tuesday said the alert seeks to advise doctors and patients to monitor the possibility of an adverse reaction of the drug. "The alert issued by IPC was to advise doctors and patients to monitor the possibility of an adverse drug reaction of mefenamic acid, which does not in any way impact the safety, efficacy and high quality of the brands that are established and supported by clinical studies," Blue Cross Laboratories, which makes meftal and meftal-spas, said in a statement. The IPC on November 30 had issued an alert on mefenamic acid stating that a preliminary analysis of adverse drug reactions from the Pharmacovigilance Programme of India (PvPI) database revealed drug reactions with eosinophilia and systemic symptoms (DRESS) syndrome. "Healthcare professionals, patients/consumers are advised to closely monitor th

Aster considering to pay 70-80% of $903 mn Gulf demerger money as dividends

The company said on Monday it plans to use the proceeds to pay shareholders between 110 rupees and 120 rupees per share as dividends